<!DOCTYPE html>
<html>
<head>
  <title>Vähiravimid</title>
  <meta charset="utf-8">
  <meta name="description" content="Vähiravimid">
  <meta name="author" content="Taavi Päll">
  <meta name="generator" content="slidify" />
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta http-equiv="X-UA-Compatible" content="chrome=1">
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/default.css" media="all" >
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/phone.css" 
    media="only screen and (max-device-width: 480px)" >
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/slidify.css" >
  <link rel="stylesheet" href="libraries/highlighters/highlight.js/css/tomorrow.css" />
  <base target="_blank"> <!-- This amazingness opens all links in a new tab. -->  <link rel=stylesheet href="./assets/css/ribbons.css"></link>

  
  <!-- Grab CDN jQuery, fall back to local if offline -->
  <script src="http://ajax.aspnetcdn.com/ajax/jQuery/jquery-1.7.min.js"></script>
  <script>window.jQuery || document.write('<script src="libraries/widgets/quiz/js/jquery.js"><\/script>')</script> 
  <script data-main="libraries/frameworks/io2012/js/slides" 
    src="libraries/frameworks/io2012/js/require-1.0.8.min.js">
  </script>
  
  

</head>
<body style="opacity: 0">
  <slides class="layout-widescreen">
    
    <!-- LOGO SLIDE -->
        <slide class="title-slide segue nobackground">
  <hgroup class="auto-fadein">
    <h1>Vähiravimid</h1>
    <h2>Onkobioloogia</h2>
    <p>Taavi Päll<br/>vanemteadur, VTAK</p>
  </hgroup>
  <article></article>  
</slide>
    

    <!-- SLIDES -->
    <slide class="" id="slide-1" style="background:;">
  <article data-timings="">
    <!-- Limit image width and height -->

<style type="text/css">
img {     
  max-height: 480px;     
  max-width: 600px; 
  }
</style>

<style> .title-slide {
background-image:url(https://pbs.twimg.com/media/B4L1taPCUAEhkGA.jpg:large);
background-repeat: no-repeat;
background-position: 87.5% 35%;
background-size: 44%;
background-color: #CBE7A5; /* ; ; */
}

.title-slide hgroup > h1{
 font-family: 'Oswald', 'Helvetica', sanserif; 
}

.title-slide hgroup > h1, 
.title-slide hgroup > h2 {
  color: #535E43 ;  /* ; #EF5150*/
}
</style>

<!-- Center image on slide -->

<script type="text/javascript" src="http://ajax.aspnetcdn.com/ajax/jQuery/jquery-1.7.min.js"></script>

<script type="text/javascript">
$(function() {     
  $("p:has(img)").addClass('centered'); 
});
</script>

<!-- Italic and Bold -->

<style>
em {
  font-style: italic
}
strong {
  font-weight: bold;
}
</style>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="segue dark nobackground" id="slide-2" style="background:;">
  <hgroup>
    <h2>Recap</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-3" style="background:;">
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-4" style="background:;">
  <hgroup>
    <h2>Immunsüsteem ja vähk</h2>
  </hgroup>
  <article data-timings="">
    
<div style='float:left;width:48%;' class='centered'>
  
</div>
<div style='float:right;width:48%;'>
  
</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="segue dark nobackground" id="slide-5" style="background:;">
  <hgroup>
    <h2>Vähiravimid</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-6" style="background:;">
  <hgroup>
    <h2>Vähitrendid 20. sajandil</h2>
  </hgroup>
  <article data-timings="">
    <p><img src="assets/fig/unnamed-chunk-1.png" alt="plot of chunk unnamed-chunk-1"> </p>

<p><footer class="source">Andmed: Long-Term Trends in Cancer Mortality in the United States, 1930 –1998. Wingo et al., 
<a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.11380/pdf">2003</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-7" style="background:;">
  <hgroup>
    <h2>Kaks peamist trendi vähisuremuses</h2>
  </hgroup>
  <article data-timings="">
    <h1>Vähi suremus peegeldab ravi efektiivsust</h1>

<ul>
<li><strong>Suremus osadesse kasvajatüüpidesse on vähenenud</strong>. Tingituna näiteks mao- ja maksakasvajate puhul paremast toiduohutusest (<em>H. pylori</em>) ja emakakaela (ja soole-) kasvajate puhul sõeltestimistest.</li>
<li><strong>Mitmed põhilised kasvajatüübid on jäänud resistentseks</strong> enamuse kasutatavate ravimeetodite suhtes.</li>
<li>Enamus laialt kasutatavatest vähiravimitest on kasutusele võetud juba enne 1970-ndaid aastaid, mil puudus arusaam vähi molekulaarsetest alustest.</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-8" style="background:;">
  <hgroup>
    <h2>Esmased vähid ja 5 aasta suremus</h2>
  </hgroup>
  <article data-timings="">
    <h1>Käärid vähi diagnoosimise ja eduka ravi vahel</h1>

<p><img src="http://www.sciencemag.org/content/vol331/issue6024/images/data/1540-a/DC1/331_1540a_F1.jpg" alt="suremus"></p>

<p><footer class="source">Pilt: Cancer Research and the $90 Billion Metaphor. Eliot Marshall, 
<a href="http://www.sciencemag.org/content/331/6024/1540.1.full">2011</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-9" style="background:;">
  <hgroup>
    <h2>Molekulaarne profileerimine aitab määrata ravi</h2>
  </hgroup>
  <article data-timings="">
    <h1>HER2/ER/PR-negatiivne rinnavähk</h1>

<div style='float:left;width:48%;' class='centered'>
  <p><img src="http://theoncologist.alphamedpress.org/content/15/suppl_5/39/F1.medium.gif" alt="her2"></p>

</div>
<div style='float:right;width:48%;'>
  <p><img src="http://theoncologist.alphamedpress.org/content/15/suppl_5/39/F2.medium.gif" alt="basal"></p>

<p><footer class="source">Pildid: Molecular Stratification of Triple-Negative Breast Cancers. Charles M. Perou, 
<a href="http://theoncologist.alphamedpress.org/content/15/suppl_5/39.long">2010</a>.
</footer></p>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-10" style="background:;">
  <hgroup>
    <h2>Molekulaarne profileerimine</h2>
  </hgroup>
  <article data-timings="">
    <h1>Difuusne suurerakuline lümfoom</h1>

<p><img src="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1351148/bin/nihms-5150-0001.jpg" alt="blümfoom"></p>

<p><footer class="source">Pilt: The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling. Louis M. Staudt
&amp; Sandeep Dave, 
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1351148/">2005</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-11" style="background:;">
  <hgroup>
    <h2>Vähiravi strateegiad</h2>
  </hgroup>
  <article data-timings="">
    <h1>Surm/apoptoos vs diferentseerumine</h1>

<ul>
<li>Enamus mittekirurgilise vähiravi strateegiatest põhineb sellel, et ravi tagajärjel <strong>vähirakud lähevad apoptoosi</strong>.</li>
<li>Alternatiiviks on vähirakkude <strong>diferentseeruma suunamine</strong> nii, et nad muutuksid post-mitootilisteks.</li>
</ul>

<p><img src="http://mct.aacrjournals.org/content/7/8/2358/F5.large.jpg" style="width:460px;"/></p>

<p><footer class="source">Pilt: 12-AAG (tanespimycin) indutseeritud mitoosikatastroof rinnavähi rakuliinidel. Zajac et al., 
<a href="http://mct.aacrjournals.org/content/7/8/2358.full">2008</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-12" style="background:;">
  <hgroup>
    <h2>Äge promüelotsüütne leukeemia</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>APL iseloomustab ebanormaalne mitte-küpsete granulotsüütide akumulatsioon ja on seotud retinoolhappe retseptori (RARα) translokatsiooniga (t(15;17)(q22;q12); PML-RAR).

<ul>
<li>Algselt fataalne haigus (kirjeldati 1957) on hästi ravitav <strong>all-trans-retinoolhappega</strong> mis diferentseerib need vähirakud neutrofiilideks.</li>
<li>all-trans-retinoolhape põhjustab diferentsatsiooni geene represseeriva PML-RAR valgu ubikvitineerimise ja proteasoomse lagundamise.</li>
</ul></li>
</ul>

<p><img src="assets/img/apl.png" alt="apl"></p>

<p><footer class="source">Pildid: image.bloodline.net, wikipedia.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-13" style="background:;">
  <hgroup>
    <h2>Ainult osa vähi valkudest sobivad ravimimärklauaks</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>Madalmolekulaarsed ühendid omavad peamiselt inhibeerivat toimet valkudele millele nad seostuvad</li>
<li>Tuumorsuppressorid ja genoomi korrashoiu eest vastutavad valgud ei sobi seega ravimi märklauaks: nende funktsiooni on vähirakkudes praktiliselt võimatu taastada.</li>
<li>Onkogeenid ja neile signaalirajas järgnevad geenid on potentsiaalsed ravimimärklauad.</li>
</ul>

<p><img src="http://www.biooncology.com/images/biological-pathways/her-main-lg.jpg" style="width:400px;"/></p>

<p><footer class="source">Pilt: <a href="http://www.biooncology.com">www.biooncology.com</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-14" style="background:;">
  <hgroup>
    <h2>Onkogeen sõltuvus</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>&#39;Onkogeen sõltuvus&#39; (<a href="http://carcin.oxfordjournals.org/content/21/5/857.abstract?ijkey=a8731bb91ca8497327c79918f8012a574b2a93b5&amp;keytype2=tf_ipsecsha"><em>oncogene addiction</em></a>): vaatamata tumorigeneesi käigus vähirakku akumuleerunud mitmete onkogeensetele mutatsioonidele, on vähirakk sõltuv kindla onkogeense valgu/raja aktivatsioonist. </li>
<li>Kui see kriitiline rada &#39;kinni panna&#39; siis vähk kollapseerub 

<ul>
<li>BCR-ABL fuusionvalk kroonilises müelotsüütses leukeemias on tundlik imatinib-le,</li>
<li>HER2 on amplifitseerunud 25-30% rinnavähkides mis muudab need tundlikuks HER2-antikehadele (trastuzumab) ja inhibiitoritele (lapatinib),</li>
<li>EGFR 10-20% mitte-väikserakulised kopsuvähid sisaldavad aktiveerivaid mutatsioone kinaasses domäänis ja on tundlikud inhibiitoritele gefitinib ja erlotinib-ile,</li>
<li>BRAF V600E mutatsioon on 70% melanoomides, 40% kilpnäärmevähkides ja 20% mCRC mis muudab need tundlikuks nt. vemurafenib-ile.</li>
</ul></li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-15" style="background:;">
  <hgroup>
    <h1>Eksperimentaalsed näited onkogeen sõltuvusest</h1>
  </hgroup>
  <article data-timings="">
    <table><thead>
<tr>
<th>Transgeenne onkogeen</th>
<th>vähi vastus</th>
</tr>
</thead><tbody>
<tr>
<td>Vähi täielik regressioon peale transgeeni &#39;välja lülitamist&#39;</td>
<td></td>
</tr>
<tr>
<td>H-ras</td>
<td>melanoom kollapseerus</td>
</tr>
<tr>
<td>K-ras</td>
<td>kopsu adenokartsinoomi regressioon</td>
</tr>
<tr>
<td>bcr-abl</td>
<td>B-raku leukeemia regressioon</td>
</tr>
<tr>
<td>myc</td>
<td>T raku lümfoom, AML regressioon</td>
</tr>
<tr>
<td>fgf-7</td>
<td>kopsu epiteeli hüperplaasia regressioon</td>
</tr>
<tr>
<td>SV40 LT</td>
<td>süljenäärme hüperplaasia regresseerus, kui transgeeni ekspresseeriti &lt;4 kuud</td>
</tr>
<tr>
<td>Vähk jäi alles või relapseerus peale transgeeni &#39;välja lülitamist&#39;</td>
<td></td>
</tr>
<tr>
<td>SV40 LT</td>
<td>süljenäärme hüperplaasia tuli tagasi, kui transgeeni ekspresseeriti &gt;4 kuud</td>
</tr>
<tr>
<td>neu</td>
<td>rinnanäärme adenokartsinoom relapseerus</td>
</tr>
<tr>
<td>myc või wnt</td>
<td>rinnanäärme adenokartsinoom jäi alles</td>
</tr>
</tbody></table>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-16" style="background:;">
  <hgroup>
    <h2><em>Druggable targets</em></h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-17" style="background:;">
  <hgroup>
    <h1>Kinome tree</h1>
  </hgroup>
  <article data-timings="">
    <p><img src="http://media.cellsignal.com/www/images/science/kinases/kinome.jpg" alt="kinome"></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-18" style="background:;">
  <hgroup>
    <h2>Vähiteraapias kasutatavad ravimiklassid</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>Tsütotoksilised kemoterapeutikumid,

<ul>
<li>toimivad kiirelt jagunevatele rakkudele (nt. CHOP kombo:  Cyclophosphamide, Doxorubicin, Vincristine (Oncovin), Prednisolone).</li>
</ul></li>
<li>Hormoonravimid,

<ul>
<li>blokeerivad hormoon-sõltuvate vähirakkude jagunemist ja põhjustavad vähirakkude surma (Lutron, Zytiga), </li>
</ul></li>
<li>Märklaud-ravimid,

<ul>
<li>inhibeerivad spetsiifilisi onkovalke, millest vähirakud on sõltuvad (<em>oncogene dependence</em>).</li>
</ul></li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-19" style="background:;">
  <hgroup>
    <h2>Märklaud-ravimid</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>Märklaud teraapias kasutatavad ravimid jagunevad kaheks peamiseks rühmaks

<ul>
<li>madalmolekulaarsed inhibiitorid</li>
<li><strong>monoklonaalsed antikehad</strong> (<em>rituximab,bevacizumab,trastuzumab</em>,etc)</li>
</ul></li>
<li><p>Madalmolekulaarsed inhibiitorid jagunevad omakorda mitmeks rühmaks, millest osad on: </p>

<ul>
<li><strong>türosiin kinaasi inhibiitorid</strong> (<em>imatinib mesylate,gefitinib,sorafenib, sunitinib</em>,etc), </li>
<li><strong>seriin/treoniin kinaasi inhibiitorid</strong> (<em>temsirolimus, everolimus,vemurafenib</em>,etc),</li>
<li><strong>proteasoomi inhibiitorid</strong> (<em>bortezomib</em>).</li>
</ul></li>
<li><p>Näiteid <a href="http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/">märklaud-ravimitest</a></p></li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-20" style="background:;">
  <hgroup>
    <h2>Kinaasi inhibiitorid vähiravis</h2>
  </hgroup>
  <article data-timings="">
    <p>A total of 24 small-molecule kinase inhibitors have
been approved for use as therapeutic agents, 17 of which are for
cancer. In addition, four monoclonal antibodies acting on protein
kinase targets have also been licensed for cancer therapy.</p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-21" style="background:;">
  <hgroup>
    <h2>EGFR inhibiitorid</h2>
  </hgroup>
  <article data-timings="">
    <h1>Chemical structures of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and their molecular modes of binding to the target.</h1>

<p><img src="http://www.nature.com/clpt/journal/v93/n3/images/clpt2012237f1.gif" alt=""></p>

<p><footer class="source"> (a) Two-dimensional (2D) structure of reversible inhibitor gefitinib and the three-dimensional (3D) structure in complex with EGFR (PDB code 3UG2). (b) 2D structure of reversible inhibitor erlotinib and the 3D structure of the binding site of EGFR in complex with erlotinib (PDB code 4HJO). (c) 2D structure of the potent irreversible inhibitor afatinib (BIBW-2992) and the 3D structure of the binding site of EGFR in complex with afatinib, showing the covalent interaction with Cys797, highlighted in orange (PDB code 4G5J). PDB, Protein Data Bank. 
 Allikas: de Castro et al., 
<a href="http://www.nature.com/clpt/journal/v93/n3/full/clpt2012237a.html">2013</a>.
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-22" style="background:;">
  <hgroup>
    <h1>&#39;Top 10 best-sellerit&#39; vähiravimite hulgas 2013 (maailmas)</h1>
  </hgroup>
  <article data-timings="">
    <table><thead>
<tr>
<th>Bränd</th>
<th>näidustus</th>
<th>märklaud</th>
<th>tüüp</th>
<th>müük</th>
<th>firma</th>
</tr>
</thead><tbody>
<tr>
<td>Rituxan</td>
<td>mitte-Hodgkini lümfoom, CLL</td>
<td>CD20</td>
<td>antikeha</td>
<td>$7.78B</td>
<td>Roche</td>
</tr>
<tr>
<td>Avastin</td>
<td>kolorektaal-, kopsu-, munasarja- ja ajuvähk</td>
<td>VEGF</td>
<td>antikeha</td>
<td>$6.75B</td>
<td>Roche</td>
</tr>
<tr>
<td>Herceptin</td>
<td>rinna-, mao- ja söögitoru vähk</td>
<td>HER2/neu</td>
<td>antikeha</td>
<td>$6.56B</td>
<td>Roche</td>
</tr>
<tr>
<td>Gleevec</td>
<td>leukeemia, GI vähk</td>
<td>BCR-ABL</td>
<td>väike kinaasi inhibiitor</td>
<td>$4.69B</td>
<td>Novartis</td>
</tr>
<tr>
<td>Alimta</td>
<td>kopsuvähk</td>
<td>puriini ja pürimidiini süntees</td>
<td>kemoterapeutikum</td>
<td>$2.7B</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Velcade</td>
<td>multi müeloom</td>
<td>valkude lagundamine</td>
<td>proteasoomi inhibiitor</td>
<td>$2.6B</td>
<td>Takeda, J&amp;J</td>
</tr>
<tr>
<td>Erbitux</td>
<td>käärsoole ja pea-kaela vähk</td>
<td>EGFR</td>
<td>antikeha</td>
<td>$1.87B</td>
<td>Merck, BMS</td>
</tr>
<tr>
<td>Lupron</td>
<td>eesnäärme ja munasarja vähk</td>
<td>gonatotropiin</td>
<td>hormoonravim</td>
<td>$1.73B</td>
<td>AbbVie, Sanofi</td>
</tr>
<tr>
<td>Zytiga</td>
<td>eesnäärme vähk</td>
<td>androgeen</td>
<td>hormoonravim</td>
<td>$1.7B</td>
<td>J&amp;J</td>
</tr>
<tr>
<td>Revlimid</td>
<td>multi müeloom, mantelrakk lümfoom</td>
<td>?</td>
<td>kemoterapeutikum</td>
<td>$1.09B</td>
<td>Celgene</td>
</tr>
</tbody></table>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="segue dark nobackground" id="slide-23" style="background:;">
  <hgroup>
    <h2>Lingid eelmistele loengutele</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-24" style="background:;">
  <article data-timings="">
    
<div style='float:left;width:48%;' class='centered'>
  <ul>
<li><a href="http://rpubs.com/tapa741/sissejuhatus">Sissejuhatav loeng</a></li>
<li><a href="http://rpubs.com/tapa741/vahityybid">Vähitüübid</a></li>
<li><a href="http://tpall.github.io/Onkoviirused">Onkoviirused</a></li>
<li><a href="http://tpall.github.io/Onkogeenid">Onkogeenid</a></li>
<li><a href="http://tpall.github.io/Retseptorid">Retseptorid</a></li>
<li><a href="http://tpall.github.io/Signaalirajad">Signaalirajad</a></li>
<li><a href="http://tpall.github.io/Tuumorsupressorid">Tuumorsupressorgeenid</a></li>
<li><a href="http://tpall.github.io/Rakutsyklikontroll">Rakutsüklikontroll</a></li>
</ul>

</div>
<div style='float:right;width:48%;'>
  <ul>
<li><a href="http://tpall.github.io/p53-ja-apoptoos">p53 ja apoptoos</a></li>
<li><a href="http://tpall.github.io/Immortalisatsioon">Immortalisatsioon</a></li>
<li><a href="http://tpall.github.io/Tumorigenees">Tumorigenees</a></li>
<li><a href="http://tpall.github.io/Genoomiterviklikkus">Genoomiterviklikkus</a></li>
<li><a href="http://tpall.github.io/Mikrokeskkond">Mikrokeskkond</a></li>
<li><a href="http://tpall.github.io/Metastaas">Metastaasid</a></li>
<li><a href="http://tpall.github.io/Immuunsus">Immuunsus</a></li>
</ul>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

    <slide class="backdrop"></slide>
  </slides>
  <div class="pagination pagination-small" id='io2012-ptoc' style="display:none;">
    <ul>
      <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=1 title=''>
         1
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=2 title='Recap'>
         2
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=3 title=''>
         3
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=4 title='Immunsüsteem ja vähk'>
         4
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=5 title='Vähiravimid'>
         5
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=6 title='Vähitrendid 20. sajandil'>
         6
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=7 title='Kaks peamist trendi vähisuremuses'>
         7
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=8 title='Esmased vähid ja 5 aasta suremus'>
         8
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=9 title='Molekulaarne profileerimine aitab määrata ravi'>
         9
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=10 title='Molekulaarne profileerimine'>
         10
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=11 title='Vähiravi strateegiad'>
         11
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=12 title='Äge promüelotsüütne leukeemia'>
         12
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=13 title='Ainult osa vähi valkudest sobivad ravimimärklauaks'>
         13
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=14 title='Onkogeen sõltuvus'>
         14
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=15 title='Eksperimentaalsed näited onkogeen sõltuvusest'>
         15
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=16 title='<em>Druggable targets</em>'>
         16
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=17 title='Kinome tree'>
         17
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=18 title='Vähiteraapias kasutatavad ravimiklassid'>
         18
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=19 title='Märklaud-ravimid'>
         19
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=20 title='Kinaasi inhibiitorid vähiravis'>
         20
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=21 title='EGFR inhibiitorid'>
         21
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=22 title='&#39;Top 10 best-sellerit&#39; vähiravimite hulgas 2013 (maailmas)'>
         22
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=23 title='Lingid eelmistele loengutele'>
         23
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=24 title=''>
         24
      </a>
    </li>
  </ul>
  </div>  <!--[if IE]>
    <script 
      src="http://ajax.googleapis.com/ajax/libs/chrome-frame/1/CFInstall.min.js">  
    </script>
    <script>CFInstall.check({mode: 'overlay'});</script>
  <![endif]-->
</body>
  <!-- Load Javascripts for Widgets -->
  
  <!-- MathJax: Fall back to local if CDN offline but local image fonts are not supported (saves >100MB) -->
  <script type="text/x-mathjax-config">
    MathJax.Hub.Config({
      tex2jax: {
        inlineMath: [['$','$'], ['\\(','\\)']],
        processEscapes: true
      }
    });
  </script>
  <script type="text/javascript" src="http://cdn.mathjax.org/mathjax/2.0-latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  <!-- <script src="https://c328740.ssl.cf1.rackcdn.com/mathjax/2.0-latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
  </script> -->
  <script>window.MathJax || document.write('<script type="text/x-mathjax-config">MathJax.Hub.Config({"HTML-CSS":{imageFont:null}});<\/script><script src="libraries/widgets/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"><\/script>')
</script>
<!-- LOAD HIGHLIGHTER JS FILES -->
  <script src="libraries/highlighters/highlight.js/highlight.pack.js"></script>
  <script>hljs.initHighlightingOnLoad();</script>
  <!-- DONE LOADING HIGHLIGHTER JS FILES -->
   
  </html>